Roche Diagnostics' Endotrophin Test Prototype
In a significant advancement for cardiovascular research, Roche Diagnostics has announced the availability of its Endotrophin (ETP) research prototype assay at Nordic Bioscience's laboratory. This development holds the promise of enhancing diagnostic capabilities, particularly for conditions related to cardiovascular, renal, and metabolic diseases.
The ETP assay is a sandwich immunoassay designed to quantify the intact 77-amino acid hormone known as endotrophin. This hormone acts as a propeptide released during type VI collagen assembly. Research indicates a strong correlation between increased endotrophin levels and severe outcomes in patients suffering from heart and kidney conditions.
Nordic Bioscience, based in Herlev, Denmark, has already measured endotrophin levels in over 50,000 patients dealing with cardio-renal and metabolic disorders. The findings suggest that elevated endotrophin is associated with higher mortality rates and unfavorable results, particularly in patients experiencing heart failure with preserved ejection fraction (HFpEF).
Notably, the U.S. Food and Drug Administration (FDA) has extended its support for further studies on endotrophin. These investigations are essential for validating endotrophin as a valuable risk stratification tool in clinical settings for HFpEF. It allows for the assessment of fibro-inflammatory risk that goes beyond traditional markers like PREVENT and NT-proBNP.
In chronic kidney disease, endotrophin levels fluctuate substantially with disease progression, serving as an indicator of declining kidney function. This makes endotrophin not just a risk marker but a potential therapeutic target, suggesting its role extends into treatment landscapes as well. Mendelian randomization studies have hinted at a causal relationship between endotrophin and coronary artery disease, while knockout models show that targeting endotrophin could protect against renal fibrosis and functional loss.
Morten Karsdal, CEO of Nordic Bioscience, emphasized that endotrophin is more than just a biomarker; it's a critical target for intervention. As research evolves, endotrophin emerges as a successor to existing biomarkers, presenting a new narrative akin to what was once understood about TNF-alpha.
A Partnership Moving Forward
The introduction of the ETP assay marks the second biomarker resulting from the synergy between Nordic Bioscience and Roche Diagnostics, following the launch of the Elecsys® PRO-C3, which was CE-marked. This collaboration underscores Roche's commitment to advancing the field of biomarker development and improving patient outcomes through better diagnostic tools.
Nordic Bioscience, with its emphasis on extracellular matrix (ECM)-focused biomarkers, combines preclinical and clinical research expertise to foster effective decision-making in clinical trials. This holistic approach enables the pharmaceutical industry to select and develop compounds with greater precision, while simultaneously providing added value in patient diagnostics.
As healthcare continues to evolve, the role of biomarkers like endotrophin will undoubtedly grow, ushering in a new era of targeted therapies and personalized medicine. The joint efforts of Roche Diagnostics and Nordic Bioscience stand as a testament to the potential that such innovations have to improve patient care in cardiometabolic health.
For more information about Nordic Bioscience and its pioneering work in biomarker development, visit
Nordic Bioscience.